What Was Approved?
On August 27, 2026, the U.S. Food and Drug Administration approved Lisraya (brepocitinib) for the treatment of dermatomyositis in adults.
Lisraya is the first FDA-approved oral treatment specifically indicated for adult dermatomyositis.
What Is Dermatomyositis?
Dermatomyositis is a rare autoimmune disease that can affect both muscles and skin.
It may cause symptoms such as:
- Progressive muscle weakness
- Skin rash
- Fatigue
- Difficulty with daily physical activities
Because the condition can affect different parts of the body, treatment is usually individualized.
How Does Lisraya Work?
Lisraya is a Janus kinase (JAK)/TYK2 inhibitor.
It works by blocking signaling pathways involved in immune and inflammatory activity.
By reducing these signals, the medicine may help decrease inflammation that contributes to muscle and skin symptoms in dermatomyositis.
How Is Lisraya Taken?
According to the FDA approval announcement, Lisraya is an oral tablet taken once daily.
Patients should follow the exact dosing instructions in the prescribing information and from their healthcare provider.
What Did the Clinical Study Show?
FDA reviewed data from a phase 3 randomized, double-blind, placebo-controlled study involving 241 adults with dermatomyositis.
The main measure of benefit was the Total Improvement Score, which evaluates several areas of disease activity, including muscle strength, physical function, skin involvement, laboratory measures, and overall patient and physician assessments.
Participants receiving Lisraya 30 mg once daily had greater overall improvement at week 52 than those receiving placebo. Improvements were also reported in physical function and skin disease activity.
What Are the Common Side Effects?
The FDA reported common adverse reactions including:
- Upper respiratory tract infection
- Headache
- Fatigue
- Urinary tract infection
- Nausea
Not every patient will experience these effects, and the complete safety profile should be reviewed in the official prescribing information.
Does Lisraya Have a Boxed Warning?
Yes.
The FDA announcement states that Lisraya carries a boxed warning for serious risks including:
- Serious infections
- Increased all-cause mortality
- Malignancies
- Major adverse cardiovascular events
- Thrombosis
These warnings are important when considering whether treatment is appropriate for an individual patient.
Who Should Discuss This Treatment With a Specialist?
Lisraya is approved for adults with dermatomyositis, but treatment decisions depend on individual factors such as:
- Disease severity
- Current medications
- Infection history
- Cardiovascular risk
- Cancer history
- Other medical conditions
Patients should discuss the potential benefits and risks with a clinician experienced in treating autoimmune or inflammatory disease.
Why Is This Approval Important?
Dermatomyositis is a rare disease with limited specifically approved treatment options.
The approval of Lisraya introduces a new oral option and gives clinicians another FDA-approved treatment choice for adults living with the condition.
Bottom Line
Lisraya (brepocitinib) is the first FDA-approved oral medicine specifically indicated for adults with dermatomyositis.
Its approval provides a new treatment option, but the medicine also carries important safety warnings that require careful patient selection and monitoring.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults, August 27, 2026.
- U.S. Food and Drug Administration (FDA) — FDA Newsroom, August 27, 2026.
- FDA Global Substance Registration System — Brepocitinib.